

Yong-xian Hu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2185916/publications.pdf>

Version: 2024-02-01

114
papers

2,132
citations

279798

23
h-index

302126

39
g-index

121
all docs

121
docs citations

121
times ranked

2750
citing authors

#	ARTICLE	IF	CITATIONS
1	Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. <i>Journal of Hematology and Oncology</i> , 2020, 13, 153.	17.0	172
2	Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. <i>Journal of Hematology and Oncology</i> , 2016, 9, 70.	17.0	151
3	Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt/ β -catenin signaling pathway. <i>Journal of Hematology and Oncology</i> , 2015, 8, 1.	17.0	122
4	CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 2764-2772.	7.0	122
5	Potent Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 3297-3306.	7.0	106
6	Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1092-1098.	2.0	79
7	Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia. <i>Experimental Hematology and Oncology</i> , 2017, 6, 10.	5.0	64
8	Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study. <i>Journal of Hematology and Oncology</i> , 2020, 13, 42.	17.0	56
9	Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. <i>BMC Cancer</i> , 2021, 21, 606.	2.6	52
10	First-in-Man CD123-Specific Chimeric Antigen Receptor-Modified T Cells for the Treatment of Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3778-3778.	1.4	43
11	Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapy. <i>Journal of Leukocyte Biology</i> , 2017, 102, 1347-1356.	3.3	40
12	Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia. <i>Molecular Therapy</i> , 2021, 29, 645-657.	8.2	39
13	Metallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/ β -catenin signaling pathway. <i>BMC Cancer</i> , 2017, 17, 161.	2.6	38
14	Risk and prognostic factors of transplantation-associated thrombotic microangiopathy in allogeneic haematopoietic stem cell transplantation: a nested case control study. <i>Hematological Oncology</i> , 2017, 35, 821-827.	1.7	37
15	A retrospective comparison of allogeneic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia. <i>Bone Marrow Transplantation</i> , 2019, 54, 1208-1217.	2.4	37
16	CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study. <i>Cancer Immunology Research</i> , 2021, 9, 1061-1070.	3.4	37
17	Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. <i>Blood</i> , 2022, 139, 3376-3386.	1.4	36
18	mTOR inhibition improves the immunomodulatory properties of human bone marrow mesenchymal stem cells by inducing COX-2 and PGE2. <i>Stem Cell Research and Therapy</i> , 2017, 8, 292.	5.5	35

#	ARTICLE	IF	CITATIONS
19	Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion. <i>Journal of Hematology and Oncology</i> , 2021, 14, 113.	17.0	32
20	CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges. <i>Current Research in Translational Medicine</i> , 2020, 68, 111-118.	1.8	30
21	Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction. <i>Frontiers in Immunology</i> , 2021, 12, 627764.	4.8	28
22	Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 713577.	2.8	27
23	Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 6384-6392.	7.0	27
24	Current development of chimeric antigen receptor T-cell therapy. <i>Stem Cell Investigation</i> , 2018, 5, 44-44.	3.0	26
25	Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy. <i>Bone Marrow Transplantation</i> , 2021, 56, 570-580.	2.4	25
26	Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study. <i>Oncolimmunology</i> , 2017, 6, e1277307.	4.6	24
27	CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study. <i>Annals of Hematology</i> , 2018, 97, 781-789.	1.8	24
28	New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 702644.	2.8	24
29	Inhibition of Calcium Signaling Prevents Exhaustion and Enhances Anti-Leukemia Efficacy of CAR-T Cells via SOCE and Calcineurin/NFAT and Glycolysis Pathways. <i>Advanced Science</i> , 2022, 9, e2103508.	11.2	21
30	A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 105.	6.2	20
31	A promising sword of tomorrow: Human γ T cell strategies reconcile allo-HSCT complications. <i>Blood Reviews</i> , 2016, 30, 179-188.	5.7	19
32	γ T Cell and Other Immune Cells Crosstalk in Cellular Immunity. <i>Journal of Immunology Research</i> , 2014, 2014, 1-8.	2.2	18
33	Quantitative characterization of T-cell repertoire alteration in Chinese patients with B-cell acute lymphocyte leukemia after CAR-T therapy. <i>Bone Marrow Transplantation</i> , 2019, 54, 2072-2080.	2.4	18
34	Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma. <i>Journal of Zhejiang University: Science B</i> , 2020, 21, 29-41.	2.8	17
35	Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. <i>Stem Cell Investigation</i> , 2021, 8, 1-1.	3.0	17
36	CXCR4 Antagonist AMD3100 Promotes Mesenchymal Stem Cell Mobilization in Rats Preconditioned with the Hypoxia-Mimicking Agent Cobalt Chloride. <i>Stem Cells and Development</i> , 2018, 27, 466-478.	2.1	16

#	ARTICLE	IF	CITATIONS
37	Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies. <i>Cell Transplantation</i> , 2020, 29, 096368972091943.	2.5	16
38	Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-cell Malignancies. <i>Cell Transplantation</i> , 2021, 30, 096368972110255.	2.5	16
39	Cytotoxicity of Donor Natural Killer Cells to Allo-Reactive T Cells Are Related With Acute Graft-vs.-Host-Disease Following Allogeneic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 1534.	4.8	15
40	Understanding of cytokines and targeted therapy in macrophage activation syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 198-210.	3.4	14
41	CRS-related coagulopathy in BCMA targeted CART therapy: a retrospective analysis in a phase I/II clinical trial. <i>Bone Marrow Transplantation</i> , 2021, 56, 1642-1650.	2.4	14
42	Potent Anti-Tumor Activity of Bcma CAR-T Therapy Against Heavily Treated Multiple Myeloma and Dynamics of Immune Cell Subsets Using Single-Cell Mass Cytometry. <i>Blood</i> , 2019, 134, 1859-1859.	1.4	14
43	Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2022, 12, 20.	6.2	14
44	Rapamycin together with TGF- β 1, IL-2 and IL-15 induces the generation of functional regulatory T cells from human peripheral blood mononuclear cells. <i>Journal of Immunological Methods</i> , 2014, 402, 82-87.	1.4	13
45	Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy. <i>Bone Marrow Transplantation</i> , 2019, 54, 969-972.	2.4	13
46	Phenotypical and Functional Characterization of Bone Marrow Mesenchymal Stem Cells in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1020-1028.	2.0	12
47	Prophylactic modified donor lymphocyte infusion after low-dose ATG-F-based haploidentical HSCT with myeloablative conditioning in high-risk acute leukemia: a matched-pair analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 664-672.	2.4	12
48	Efficacy of anti-CD19 chimeric antigen receptor modified T(CAR-T) cell therapy in Chinese patients with relapsed/refractory acute lymphocytic leukemia in a multicenter trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7028-7028.	1.6	12
49	Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse. <i>Frontiers in Oncology</i> , 2021, 11, 750218.	2.8	12
50	CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma: a Safety and Efficacy Study. <i>Blood</i> , 2020, 136, 34-34.	1.4	11
51	Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy. <i>Cancer Research and Treatment</i> , 2018, 50, 1462-1466.	3.0	11
52	Phase I open-label single arm study of GPRC5D CAR T-cells (OriCAR-017) in patients with relapsed/refractory multiple myeloma (POLARIS).. <i>Journal of Clinical Oncology</i> , 2022, 40, 8004-8004.	1.6	11
53	Determining Whether Prophylactic Antiviral Treatment Is Necessary in HBsAg-Negative/HBcAb-Positive Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 956-964.	2.0	10
54	Reduction of Foxp3+ T cell subsets involved in incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Hematological Oncology</i> , 2017, 35, 118-124.	1.7	9

#	ARTICLE	IF	CITATIONS
55	Generation of hematopoietic cells from mouse pluripotent stem cells in a 3D culture system of self-assembling peptide hydrogel. <i>Journal of Cellular Physiology</i> , 2020, 235, 2080-2090.	4.1	9
56	Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma. <i>Medicine (United States)</i> , 2020, 99, e22510.	1.0	9
57	The emerging landscape of exosomal CircRNAs in solid cancers and hematological malignancies. <i>Biomarker Research</i> , 2022, 10, 28.	6.8	9
58	Relapsing Hematologic Malignancies after Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1099-1111.	2.0	8
59	Allogeneic hematopoietic stem cell transplantation should be in preference to conventional chemotherapy as post-remission treatment for adults with lymphoblastic lymphoma. <i>Bone Marrow Transplantation</i> , 2018, 53, 1340-1344.	2.4	8
60	Successful chimeric antigen receptor T cells therapy in extramedullary relapses of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1476-1478.	2.4	8
61	A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma. <i>Frontiers of Medicine</i> , 2020, 14, 711-725.	3.4	8
62	Bullous and Exanthematous Lesions Associated With Chimeric Antigen Receptor T-Cell Therapy in a Patient With Diffuse Large B-Cell Lymphoma. <i>JAMA Dermatology</i> , 2020, 156, 1026.	4.1	8
63	BCMA CAR-T Therapy Is Safe and Effective for Refractory/Relapsed Multiple Myeloma With Central Nervous System Involvement. <i>Journal of Immunotherapy</i> , 2021, Publish Ahead of Print, 25-34.	2.4	8
64	The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2020, 136, 52-52.	1.4	8
65	ICT1 predicts a poor survival and correlated with cell proliferation in diffuse large B-cell lymphoma. <i>Gene</i> , 2017, 627, 255-262.	2.2	7
66	Profile of Capillary-Leak Syndrome in Patients Received Chimeric Antigen Receptor T Cell Therapy. <i>Blood</i> , 2018, 132, 5204-5204.	1.4	7
67	Cunninghamella bertholletiae Infection in a HLA-Haploidentical Hematopoietic Stem Cell Transplant Recipient with Graft Failure: Case Report and Review of the Literature. <i>Mycopathologia</i> , 2016, 181, 753-758.	3.1	6
68	Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report. <i>BMC Cancer</i> , 2019, 19, 242.	2.6	6
69	CD19/CD22 chimeric antigen receptor T-cell therapy for refractory acute B-cell lymphoblastic leukemia with FLT3-ITD mutations. <i>Bone Marrow Transplantation</i> , 2020, 55, 717-721.	2.4	6
70	Maintenance sorafenib is superior to prophylactic donor lymphocyte infusion at improving the prognosis of acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 293-296.	2.4	6
71	Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome—A Wandering Road to Remission. <i>Frontiers in Oncology</i> , 2021, 11, 755584.	2.8	6
72	Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma. <i>Current Oncology</i> , 2022, 29, 490-496.	2.2	6

#	ARTICLE	IF	CITATIONS
73	Donor-Derived Solid Malignancies after Hematopoietic Stem Cell Transplantation. <i>Onkologie</i> , 2010, 33, 195-200.	0.8	5
74	Ruxolitinib treatment for acute gastrointestinal graft-versus-host disease caused by donor-derived CD19-Chimeric antigen receptor T-Cell infusion in a patient with B-ALL relapsed after Allo-HSCT. <i>Regenerative Therapy</i> , 2019, 11, 139-142.	3.0	5
75	Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment. <i>Journal of Cancer</i> , 2021, 12, 5423-5431.	2.5	5
76	Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies. <i>Current Medical Science</i> , 2021, 41, 420-430.	1.8	5
77	Cell subsets and cytokine dynamics in cerebrospinal fluid after CAR-T cell therapy for B-cell acute lymphoblastic leukemia with central nervous system involvement. <i>Bone Marrow Transplantation</i> , 2021, 56, 3088-3090.	2.4	5
78	SNX2A ABL1-positive acute lymphoblastic leukemia possibly has a poor prognosis. <i>Leukemia and Lymphoma</i> , 2017, 58, 2261-2263.	1.3	4
79	Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy. <i>Regenerative Therapy</i> , 2020, 15, 281-284.	3.0	4
80	CAR-T cells: the Chinese experience. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1293-1308.	3.1	4
81	COVID-19 in Hematologic Malignancies: Big Challenges. <i>Clinical Hematology International</i> , 2020, 2, 173.	1.7	4
82	The role of pre-treatment and mid-treatment 18F-FDG PET/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS). <i>BMC Medical Imaging</i> , 2021, 21, 145.	2.7	4
83	Early detection and intervention of clonal hematopoiesis for preventing hematological malignancies. <i>Cancer Letters</i> , 2022, 538, 215691.	7.2	4
84	Withdrawal: Generation of hematopoietic cells from mouse pluripotent stem cells in a 3D culture system of self-assembling peptide hydrogel. <i>Journal of Cellular Physiology</i> , 2019, 234, 16654-16654.	4.1	3
85	Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy. <i>Regenerative Therapy</i> , 2020, 14, 271-274.	3.0	3
86	Successful treatment of T3151 BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib. <i>Regenerative Therapy</i> , 2020, 14, 40-42.	3.0	3
87	Efficacy of CD19-targeted chimeric antigen receptor T cells in the treatment of relapsed extramedullary B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2017, 35, e14549-e14549.	1.6	3
88	Nutritional status alterations after chimeric antigen receptor T cell therapy in patients with hematological malignancies: a retrospective study. <i>Supportive Care in Cancer</i> , 2022, 30, 3321-3327.	2.2	3
89	The CD226/ERK1/2/LAMP1 pathway is an important mechanism for V β 3V γ 2 T cell cytotoxicity against chemotherapy-resistant acute myeloid leukemia blasts and leukemia stem cells. <i>Cancer Science</i> , 2021, 112, 3233-3242.	3.9	2
90	Cytokine Release Syndrome Is an Independent Risk Factor Associated With Platelet Transfusion Refractoriness After CAR-T Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Frontiers in Pharmacology</i> , 2021, 12, 702152.	3.5	2

#	ARTICLE	IF	CITATIONS
91	Weathering the storm: COVID-19 infection in patients with hematological malignancies. Journal of Zhejiang University: Science B, 2020, 21, 921-939.	2.8	2
92	Integrated Single-Cell Bioinformatics Analysis Reveals Intrinsic and Extrinsic Biological Characteristics of Hematopoietic Stem Cell Aging. Frontiers in Genetics, 2021, 12, 745786.	2.3	2
93	Profile of capillary-leak syndrome in patients received chimeric antigen receptor T cell therapy. Bone Marrow Transplantation, 2022, , .	2.4	2
94	Predictive value of next-generation sequencing-based minimal residual disease after CAR-T cell therapy. Bone Marrow Transplantation, 2022, 57, 1350-1353.	2.4	2
95	Pomalidomide-based regimens bridging CAR-T therapy in multiple myeloma with central nervous system involvement. Regenerative Therapy, 2022, 21, 34-36.	3.0	2
96	Phytohemagglutinin-activated human T cells induce lethal graft-versus-host disease in cyclophosphamide and anti-CD122 conditioned NOD/SCID mice. Annals of Hematology, 2012, 91, 1803-1812.	1.8	1
97	Improved survival for young acute leukemia patients following a new donor hierarchy for allogeneic hematopoietic stem cell transplantation: A phase III randomized controlled study. American Journal of Hematology, 2021, 96, 1429-1440.	4.1	1
98	Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-Cell Malignancies. Blood, 2019, 134, 3220-3220.	1.4	1
99	Foxp3+ Regulatory T Cell Subsets Are Induced In Alloreactive Microenvironment and Associated With Chronic Graft-Versus-Host Disease Severity After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 3307-3307.	1.4	1
100	Changes of T Lymphocyte Subsets after CAR-T Cell Therapy and Its Clinical Significance. Blood, 2018, 132, 1423-1423.	1.4	1
101	Clinical Characterization and Risk Factors Associated with Cytokine Release Syndrome Induced By COVID-19 and Chimeric Antigen Receptor T-Cell Therapy. Blood, 2020, 136, 35-36.	1.4	1
102	Outcomes of CD19 chimeric antigen receptor T cell followed by haploidentical hematopoietic stem-cell transplantation in relapsed/refractory B-cell acute lymphoblastic leukemia with IKZF1 deletion. Bone Marrow Transplantation, 2022, 57, 326-328.	2.4	1
103	é¶áCD19áµCEáæŠ—áŽŸá—á½“Tç»†èfžæ²»ç—æCYæESBæ·á·ç»†èfžç™¹/²èjç—...á¼é«“á—áá·æ,Éè€...çš,,á®%á.3.”æ€Sá’CEææ%ç		
104	CAR-Tç»†èfžæ²èjçæ¶²ç³»ç»†æ¶æ€Sè,ç~æ²»ç—çš,,ç”ç©¶èj;á±•. Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University		
105	CAR-T cells for cancer immunotherapyâ€”the barriers ahead and the pathsâ€”through. International Reviews of Immunology, 2022, 41, 567-581.	3.3	1
106	The effectiveness of interferon-Î± combined with imatinib in patient with chronic myeloid leukemia harboring T315I <i>BCR-ABL1</i> mutation. Leukemia and Lymphoma, 2018, 59, 3018-3019.	1.3	0
107	Bronchiolitis Obliterans Following Unrelated-Donor Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2010, 116, 4504-4504.	1.4	0
108	Allogeneic Hematopoietic Stem Cell Transplantation From HBsAg-Positive Donors Into HBsAg-Negative Recipients: A Safety and Practicable Regimen Under Active Prophylactic Anti-HBV Therapy. Blood, 2011, 118, 1949-1949.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Ex Vivo-Expanded VÎ³9VÎ²2 T Cells Can Efficiently Kill Human Acute Myeloid Leukemia Cells Via Trogocytosis. <i>Blood</i> , 2011, 118, 580-580.	1.4	0
110	Regular Prophylactic Donor Lymphocyte Infusion Is Effective and Safe to Prevent Relapse after Hematopoietic Cell Transplantation in High-Risk Patients. <i>Blood</i> , 2016, 128, 3439-3439.	1.4	0
111	Expansion of CD56-Bright NK Cell in Patients with Steroid-Refractory Graft-Versus-Host Disease Treated with Basiliximab and Etanercept. <i>Blood</i> , 2016, 128, 5793-5793.	1.4	0
112	Predictive Value of Next-Generation Sequencing-Based Minimal Residual Disease after CAR-T Cell Therapy. <i>Blood</i> , 2021, 138, 2842-2842.	1.4	0
113	HLAâ€mismatched allogeneic antiâ€CD19 CARâ€T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden. <i>Immunomedicine</i> , 2022, 2, .	0.7	0
114	Preliminary safety and efficacy of relmacabtagene autoleucel (relma-cel) as second-line therapy for primary refractory Chinese patients with large B-cell lymphoma (LBCL): Results from an open-label, multicenter, single-arm phase I study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19509-e19509.	1.6	0